Neurocrine Biosciences (NBIX) Cash from Investing Activities Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | 91.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -366.90% |
| Mar 31, 2026 | -3,664.79% |
| Dec 31, 2025 | 22.55% |
| Sep 30, 2025 | -896.36% |
| Jun 30, 2025 | -2.84% |
| Mar 31, 2025 | 125.82% |
| Dec 31, 2024 | 66.15% |
| Sep 30, 2024 | 125.39% |
| Jun 30, 2024 | 77.60% |
| Mar 31, 2024 | -30.64% |
| Dec 31, 2023 | -74.57% |
| Sep 30, 2023 | -58.73% |
| Jun 30, 2023 | -500.96% |
| Mar 31, 2023 | -33.23% |
| Dec 31, 2022 | -587.76% |
| Sep 30, 2022 | 51.43% |
| Jun 30, 2022 | 134.58% |
| Mar 31, 2022 | -150.08% |
| Dec 31, 2021 | 116.05% |
| Sep 30, 2021 | -600.79% |